Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.56 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20980386 | 0.95 | CPB1 (0.60) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL14642693 | 0.92 | CPB1 (0.58) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL14642690 | 0.90 | SIRT2 (0.61) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL24152588 | 0.90 | CPB1 (0.65) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL24152589 | 0.90 | CPB1 (0.65) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL15084866 | 0.89 | SIRT2 (0.61) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL22055423 | 0.88 | SIRT2 (0.63) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL13387692 | 0.88 | MAPT (0.58) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL30094705 | 0.88 | SIRT2 (0.61) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL15084702 | 0.87 | SIRT2 (0.59) | CPB1CPB2SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9393315-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | CPB1 3859/4885CPB2 4199/4885SIRT2 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.